RECCE PHARMACEUTICALS LTD
ASX:RCEPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 93.7% of what they think they own, once every option and right converts.
Share count grew 29% in 24 months; runway 4–8 quarters; 1 cash raise in 24 months
RECCE PHARMACEUTICALS LTD's ordinary share count grew 29.3% between September 2024 and August 2026, its latest share-count filing, to 306M shares. The company completed one capital raising in the past 24 months, a Placement and Share Purchase Plan (SPP) in June 2026 for A$6.4M total proceeds. Options and rights on issue could convert into 21M new shares, representing 6.7% of the current share count, none of which are in the money at the current share price; the nearest expiry is in February 2027. The company has more than 4 quarters of funding at the recent spend rate. No proposed securities issues are pending.
Quick answers · 3
When did RCE last raise capital?
The last capital raise in Recce Pharmaceuticals's filings is Placement and Share Purchase Plan (SPP) of $6.4M announced 26 June 2026, one of 1 cash raises in 24 months.
How much cash does RCE have?
In its quarterly cash report for the quarter ended 30 June 2026, Recce Pharmaceuticals reported $2.9M of cash and estimated 10.9 quarters of funding available at its current rate of spending. That is the company's own estimate.
When do RCE's options expire?
Unexercised options and rights equal 6.7% of Recce Pharmaceuticals's shares on issue; the nearest expiry is Feb 2027.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 16 Oct 2026 | 3G · unquoted | RCE : ORDINARY FULLY PAID | 305.8M | Appendix 3G |
| 1 Oct 2026 | 3H · cancellation | RCE : ORDINARY FULLY PAID | 305.8M | Appendix 3H |
| 3 Aug 2026 | 2A · quoted issue | RCE : ORDINARY FULLY PAID | 299.7M | Appendix 2A |
| 31 July 2026 | 2A · quoted issue | RCE : ORDINARY FULLY PAID | 305.5M | Appendix 2A |
| 3 July 2026 | 2A · quoted issue | RCE : ORDINARY FULLY PAID | 299.5M | Appendix 2A |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
1 cash raise in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
At $0.32 today, 0 securities are in the money (0.0% of shares on issue). At double today’s price it is 2.4M (0.8% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 6.3M (30.4% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| RCEAW | Options | Price-triggered | $1.56 | 11 Feb 2027 | 435k | Filing |
| RCEAO | Options | Price-triggered | $0.56 | 7 Nov 2029 | 2.4M | Filing |
| RCEAP | Options | Price-triggered | $0.80 | 14 Nov 2029 | 11.5M | Filing |
| — | Warrants | Price-triggered, no exercise price stated | — | 15 Oct 2031 | 493k | Filing |
| RCEAU | Options | Price-triggered, no exercise price stated | — | — | 1.1M | Filing |
| RCEAQ | Warrants | Price-triggered, no exercise price stated | — | — | 4.6M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 31 July 2026 | Dr Alan Dunton | Buy entitlement/SPP | 38k | — | — | — | 3Y notice |
| 31 July 2026 | Dr John Prendergast | Buy entitlement/SPP | 38k | — | — | — | 3Y notice |
| 31 July 2026 | Dr Justin Ward | Buy entitlement/SPP | 75k | 1.0M | — | — | 3Y notice |
| 31 July 2026 | James Graham | Buy entitlement/SPP | 25k | 3.0M | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.